Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEHAM: Colistimethate sodium for MDR decolonization
NCT02966457Phase 4Completed
- Sponsor
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of colistimethate sodium in gram-negative bacterial colonization (2 arms), sponsored by Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology. Primary endpoint: Rate of eradication of MDR Gram-negative bacteria. Started Jan 2017; status: completed.
02
Drugs
colistimethate sodium
03
Conditions
gram-negative bacterial colonization
Beyond the preview
Go deeper on NCT02966457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966457.